fluticasone furoate + vilanterol + tiotropium

Fluticasone furoate + vilanterol + tiotropium is a triple combination consisting of an inhaled corticosteroid (fluticasone furoate), a long-acting β2 adrenergic agonist (vilanterol), and a long-acting muscarinic antagonist (tiotropium). This combination is designed for inhalation therapy to improve lung function and reduce exacerbations in patients with moderate to severe chronic obstructive pulmonary disease (COPD), particularly those at risk for cardiovascular disease. - Mechanism of action: - Fluticasone furoate suppresses airway inflammation by binding the glucocorticoid receptor, reducing cytokine production and immune cell recruitment. - Vilanterol activates the β2 adrenergic receptor causing bronchial smooth muscle relaxation and bronchodilation. - Tiotropium blocks the muscarinic acetylcholine receptor M3 subtype, preventing bronchoconstriction. - This triple combination is not available as a single branded product, but the dual combination of fluticasone furoate + vilanterol (marketed as Breo Ellipta) and separate tiotropium (marketed as Spiriva) are used in clinical practice, sometimes together for triple therapy in COPD management[1][4][5]. - Currently, some triple inhaler therapies use similar agents (like Trelegy Ellipta: fluticasone furoate + vilanterol + umeclidinium), but no brand or generic product with precisely fluticasone furoate + vilanterol + tiotropium in one inhaler is approved.

Brand names

Breo ElliptaSpiriva

Other names

fluticasone furoate/vilanterol + tiotropium